Navigation Links
Johnson & Johnson Receives Approval from European Commission
Date:1/28/2011

es have been sold since its launch in 2006 in more than 50 GAVI countries. With this innovation, Crucell has become a major partner in protecting children in developing countries. Other products in Crucell's core portfolio include a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. Crucell has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. Crucell licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Pfizer/Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs over 1300 people. For more information, please visit www.crucell.com.

About Johnson & JohnsonCaring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day throughout the world.

Forward-looking statements(This press release contains "forward-looking statements". All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
2. Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
3. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
4. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
5. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
6. Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
7. Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
8. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
9. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
10. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
11. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
(Date:7/11/2014)... July 11, 2014 Bedros Keuilian is known ... title he’s earned by founding the fast-selling fitness franchise in ... their businesses. He works with successful boot camp owners on ... on the traits of the most successful boot camp owners ... important qualities. , “I’ve worked with and coached some of ...
(Date:7/11/2014)... When the mercury rises, heat can strain the ... heart, takes on a heavier load in hot weather to ... of the Harvard Men's Health Watch . , For ... than knowing their limits and drinking enough fluids. But what ... more sensitive to the heat," says Dr. Joanne Foody, Director ...
(Date:7/11/2014)... 11, 2014 As reported by Forbes ... Cocaine: Are Genetics To Blame (6/30), Indino Downey has ... and paraphernalia to smoke it with. His father, well-known ... his son inherited from him may have something to ... the news during the 1980s and 1990s for substance ...
(Date:7/11/2014)... Timex, the leader in outdoor and sports performance ... Network, the brand’s new online content portal which will ... and special product offers for consumers. , The ... the Timex IRONMAN watch brand and will serve as ... The hub will reflect the active lifestyle of Timex ...
Breaking Medicine News(10 mins):Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Timex Announces Launch of Timex Performance Network 2
... All PETCO stores nationwide will host a free pet nutrition, ... experts on Saturday, November 14 at 2 p.m. During the 30-minute, ... the nutritional needs of, their dogs ... good pet nutrition, receive an assessment of their individual, ...
... the University of Florida Proton Therapy Institute have formed a ... announcement follows the approval of the first clinical study to ... in children younger than 3 years old. ... receive proton therapy at the UF Proton Therapy Institute in ...
... issue of European Urology , the official journal ... entitled ,Are Infertile Men Less Healthy than Fertile Men? ... Salonia et al. The conclusion is that male factor ... as objectively scored with the hospital-based Charlson Comorbidity Index. ...
... In the construction industry, respiratory disease, often leading to ... major public health concern. Studies led by Deborah ... Construction, have shown that specific types of sanding tools ... these health hazards, yet the industry,s usage of the ...
... The first human embryonic stem cell treatment approved by ... limb function in rats with neck spinal cord injuries ... people with cervical damage. In January, the U.S. Food ... permission to test the UC Irvine treatment in individuals with ...
... ACCRA, Ghana -- The lives of almost 4 million ... saved every year if well-established, affordable health care interventions ... report by the national science academies of seven African ... knowledge to save lives, says the report, which calls ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:European Urology: Male factor infertility associated with comorbidities 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: